צמיחת הכנסות ב-12 חודשים נגררים: Monopar Corp (MNPR)

Monopar Therapeutics (MNPR) focuses on the B2B segment, developing tools to minimize chemotherapy side effects in clinics. The year-over-year (12-month) relative revenue growth rate reflects the development trend, with the indicator standing at 0.00. US centers that reduce treatment toxicity ensure the business's stability. The company is currently moving its promising radiopharmaceutical pipeline and targeted drugs into the early clinical testing stage.
Monopar Therapeutics - פילוחים אנליטיים ומדדי מפתח (MNPR)

This indicator measures the revenue growth rate over a rolling year, smoothing out short-term anomalies to assess the actual operational resilience of the business. For Monopar Therapeutics (MNPR), which focuses on radiopharmaceutical R&D, the TTM revenue growth rate serves as a marker for the transition from pure funding to the commercialization of innovations, where a lack of growth coupled with high research expenditures signals high risks for capital.